Rimal Mousa
Biographic Data
| ID | 9997295 |
|---|---|
| NAME | Rimal Mousa |
| GIVEN NAMES | Rimal |
| FAMILY NAME | Mousa |
| SIGNATURE | MOUSA R |
| AFFILIATIONS | University of Jordan |
| ORCID | 0000-0002-1788-0281 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Budget impact analysis of the introduction of ranibizumab’s biosimilar to the Jordanian joint procurement system
Introduction: The adoption of biologic therapies imposes a substantial financial burden on the Jordanian healthcare system. ranibizumab is prescribed for various retinal disorders, and its associated costs are considerable. The introduction of biosimilars is beneficial in retaining desired clinical parameters while providing cost relief and enhanced access to patients. Objective: To examine the budget impact and expanded access of switching to ra…
Scaling holistic e-health solutions in cancer care using a qualitative realist framework
Background: While e-health innovations have advanced cancer-care delivery in high-income countries, middle-income countries (MICs) face distinct systemic, infrastructural, and sociocultural challenges in adopting and scaling digital-health interventions. There is a growing imperative to explore how holistic digital platforms can be implemented effectively in oncology within resource-constrained settings. Objective: This study aimed to investigate…
No prominent works on this page.
Scaling holistic e-health solutions in cancer care using a qualitative realist framework
Background: While e-health innovations have advanced cancer-care delivery in high-income countries, middle-income countries (MICs) face distinct systemic, infrastructural, and sociocultural challenges in adopting and scaling digital-health interventions. There is a growing imperative to explore how holistic digital platforms can be implemented effectively in oncology within resource-constrained settings. Objective: This study aimed to investigate…
Budget impact analysis of the introduction of ranibizumab’s biosimilar to the Jordanian joint procurement system
Introduction: The adoption of biologic therapies imposes a substantial financial burden on the Jordanian healthcare system. ranibizumab is prescribed for various retinal disorders, and its associated costs are considerable. The introduction of biosimilars is beneficial in retaining desired clinical parameters while providing cost relief and enhanced access to patients. Objective: To examine the budget impact and expanded access of switching to ra…
Aflibercept (1 works) · Biosimilar (1 works) · Biosimilars and Bioanalytical Methods (1 works) · Cancer (1 works) · Digital health (1 works) · Digital Mental Health Interventions (1 works) · Grounded theory (1 works) · Health care (1 works) · Health Systems, Economic Evaluations, Quality of Life (1 works) · Market share (1 works)